From 2024 to 2028, the forecasted sold production in Germany of human blood, animal blood prepared for therapeutic, prophylactic or diagnostic uses, cultures of micro-organisms, and toxins shows consistent year-over-year growth. Starting at 280.83 million euros in 2024, it climbs to 316.61 million euros by 2028. Compared to 2023, there is a projected increase, but the data for 2023 is missing. The compound annual growth rate (CAGR) from 2024 to 2028 is steady, indicating robust market development.
Future trends to watch for include advances in biotechnology and increasing demand for innovative diagnostic and therapeutic products, potentially driving further market expansion. Regulatory changes and technological advancements may also impact these projections.
